전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-2 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
ADCLimited DatastaleGileadPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan)

Metastatic Breast Cancer ( HER2 Negative) · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MetastaticBreastCancerHER2Negati+1
Trials 1Status Recruiting
ADCLimited DatastaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#MetastaticUrothelialCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 2

SKB264 (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (SKB264))

Advanced Biliary Tract Cancer(BTC) · Advanced Biliary Tract Cancer(BTC)

#AdvancedBiliaryTractCancerBTC#ADC#Phase2#antibody-drug-conjugate#Sichuan
Trials 1Status Recruiting
ADCLimited DatastaleThe First Affiliated Hospital o…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Combined with Bevacizumab)

Platinum-resistant Recurrent Ovarian Cancer (PROC) · Platinum-resistant Recurrent Ovarian Can

#Platinum-resistantRecurrentOvari#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
ADCLimited DatastaleBiying ChenPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor)

Recurrent or Metastatic Head and Neck Carcinoma · MET

#MET#ADC#Phase2#antibody-drug-conjugate#RecurrentorMetastaticHeadandNeck+1
Trials 1Status Recruiting
ADCLimited DatastaleLi-kun ChenPhase 2

sacituzumab govitecan (Trodelvy, Sac-TMT, Sacituzumab tirumotecan, Sacituzumab tirumotecan (Sac-TMT) plus bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#Li-kun
Trials 1Status Recruiting
ADCLimited DatastaleTianjin Medical University Canc…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan combined with envafolimab)

Advanced Biliary Tract Cancers · Advanced Biliary Tract Cancers

#AdvancedBiliaryTractCancers#ADC#Phase2#antibody-drug-conjugate#Tianjin
Trials 1Status Recruiting
ADCLimited DatastaleTianjin Medical University Canc…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan plus bevacizumab)

Lung Cancer · Lung Cancer

#LungCancer#ADC#Phase2#antibody-drug-conjugate#Tianjin
Trials 1Status Recruiting
AntibodyLimited DatastaleHuashan HospitalPreclinical

Satralizumab (Satralizumab)

Neuromyelitis Optica Spectrum Disorders (NMOSD) · Neuromyelitis Optica Spectrum Disorders

#NeuromyelitisOpticaSpectrumDisor#Antibody#Preclinical#monoclonal-antibody#Huashan
Trials 1Status Recruiting
CGTLimited DatastalePeking UniversityPhase 1

ScTIL injection and B lymphocytes adjuvant (ScTIL injection and B lymphocytes adjuvant)

Digestive System Malignant Solid Tumors · Digestive System Malignant Solid Tumors

#DigestiveSystemMalignantSolidTum#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#Melanoma+2
Trials 1Status Active
AntibodyLimited DatastaleAstraZenecaPhase 2

durvalumab (Imfinzi, Selumetinib + ZEN-3694 ± Durvalumab)

MPNST; NF1 · MPNST

#MPNST#Antibody#Phase2#monoclonal-antibody#NF1+1
Trials 1Status Recruiting
CGTLimited DatastaleVittoria BiotherapeuticsPhase 1

Senza5 CART5 (Senza5 CART5)

T Cell Non-Hodgkin Lymphoma · T Cell Non-Hodgkin Lymphoma

#TCellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

sequential group (Sequential treatment of bevacizumab combined with atezolizumab, Sequential treatment of bevacizumab combined with atezolizumab (sequential group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleElevation OncologyPhase 2

Seribantumab (Seribantumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#monoclonal-antibody#Elevation
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 3

Serplulimab combined with bevacizumab and first-line chemotherapy (Serplulimab combined with bevacizumab and first-line chemotherapy)

Non-small Cell Lung Cancer Stage II; Bevacizumab · Non-small Cell Lung Cancer Stage II

#Non-smallCellLungCancerStageII#Antibody#Phase3#monoclonal-antibody#Bevacizumab+1
Trials 1Status Active
AntibodyLimited DatastaleFirst Affiliated Hospital of We…Phase 2

Serplulimab immunotherapy (Serplulimab immunotherapy)

Locally Advanced Rectal Cancer (LARC) · Locally Advanced Rectal Cancer (LARC)

#LocallyAdvancedRectalCancerLARC#Antibody#Phase2#monoclonal-antibody#First
Trials 1Status Recruiting
ADCLimited DatastaleRemeGen Co., Ltd.Phase 2

disitamab vedotin (Disitamab Vedotin, RC48, Short range radiotherapy with sequential Disitamab Vedotin combined with S-1 and xindilizumab)

Gastric Cancer · Gastric Cancer

#GastricCancer#ADC#Phase2#antibody-drug-conjugate#RemeGen
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

same period group (Simultaneous treatment of bevacizumab combined with atezolizumab, Simultaneous treatment of bevacizumab combined with atezolizumab (same period group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

Sindilizumab (Sindilizumab)

Colorectal Cancer Metastatic; Chemotherapy · Colorectal Cancer Metastatic

#ColorectalCancerMetastatic#Antibody#Phase2#monoclonal-antibody#Chemotherapy+1
Trials 1Status Recruiting

85 / 103 pages

← PreviousNext →